Blueprint Medicines

Blueprint Medicines is a precision therapy company acquired by Sanofi in 2025, operating as a focused subsidiary with enhanced global resources. The company has successfully commercialized AYVAKIT® (avapritinib) for systemic mastocytosis and GIST, validating its kinase-focused discovery platform. Its strategy centers on scaling this platform to expand into larger allergic/inflammatory disease populations and solid tumors, while incorporating new modalities like targeted protein degradation and AI/ML tools to drive future pipeline growth.

An evolved, modality-agnostic drug discovery platform rooted in deep kinase and mast cell biology, now incorporating targeted protein degradation, AI/ML tools, and translational medicine to design selective therapies.

In mastocytosis, Blueprint leads with AYVAKIT but faces emerging competition. In the larger urticaria market, it would compete against established injectable biologics. Its strategy of building a comprehensive mast cell inhibitor portfolio aims to create a durable, multi-product franchise.